Roivant Sciences Stock Investor Sentiment
| ROIV Stock | USD 11.69 0.21 1.76% |
Slightly above 67% of Roivant Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Roivant Sciences suggests that many traders are alarmed. Roivant Sciences' investing sentiment can be driven by a variety of factors including economic data, Roivant Sciences' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
33
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Roivant Sciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Roivant Sciences.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Roivant Historical Sentiment
Although Roivant Sciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Roivant, such as negative comments on social media and news outlets, may cause fear in the market and push Roivant Sciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Roivant.
Roivant |
Roivant Sciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Roivant Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Roivant Sciences Historical Investor Sentiment
Investor biases related to Roivant Sciences' public news can be used to forecast risks associated with an investment in Roivant. The trend in average sentiment can be used to explain how an investor holding Roivant can time the market purely based on public headlines and social activities around Roivant Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Roivant Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Roivant Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Roivant Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Roivant Sciences.
Far too much social signal, news, headlines, and media speculation about Roivant Sciences that are available to investors today. That information is available publicly through Roivant media outlets and privately through word of mouth or via Roivant internal channels. However, regardless of the origin, that massive amount of Roivant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Roivant Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Roivant Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Roivant Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Roivant Sciences alpha.
Roivant Sciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 28411 shares by Sukhatme Mayukh of Roivant Sciences subject to Rule 16b-3 | 07/02/2024 |
2 | Disposition of 2129 shares by Richard Pulik of Roivant Sciences at 10.8 subject to Rule 16b-3 | 07/03/2024 |
3 | Acquisition by Momtazee James C of 1570 shares of Roivant Sciences subject to Rule 16b-3 | 07/10/2024 |
4 | Disposition of 958 shares by Rakhi Kumar of Roivant Sciences at 11.0 subject to Rule 16b-3 | 07/19/2024 |
5 | Acquisition by Venker Eric of 409000 shares of Roivant Sciences at 10.8 subject to Rule 16b-3 | 07/26/2024 |
6 | Roivant Sciences Q1 2025 Earnings Preview | 08/07/2024 |
7 | Disposition of 10947 shares by Matthew Gline of Roivant Sciences at 11.48 subject to Rule 16b-3 | 08/20/2024 |
8 | Disposition of 2341 shares by Richard Pulik of Roivant Sciences at 12.0 subject to Rule 16b-3 | 08/28/2024 |
9 | Disposition of 96950 shares by Venker Eric of Roivant Sciences at 10.92 subject to Rule 16b-3 | 08/30/2024 |
10 | Immunovant stock falls 8 percent amid Graves disease program update | 09/09/2024 |
11 | Roivant Sciences Unveils New Vant Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer | 09/10/2024 |
12 | Disposition of 894 shares by Fitzgerald Meghan of Roivant Sciences at 12.12 subject to Rule 16b-3 | 09/12/2024 |
13 | Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1 | 09/18/2024 |
14 | OrganonDermavantVTAMA 1 | 09/19/2024 |
15 | Should You Invest in the First Trust Health Care AlphaDEX ETF | 09/24/2024 |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.